The Italian National External Quality Assessment Program in Molecular Genetic Testing: Results of the VII Round (2010-2011)

Author:

Censi F.1,Tosto F.1,Floridia G.1,Marra M.1,Salvatore M.1,Baffico A. M.2,Grasso M.2,Melis M. A.3,Pelo E.4,Radice P.5,Ravani A.6,Rosatelli C.7,Resta N.8,Russo S.9,Seia M.10,Varesco L.11,Falbo V.1,Taruscio D.1

Affiliation:

1. National Centre of Rare Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy

2. E. O. Ospedali Galliera, S.C. Laboratorio di Genetica, 16128 Genova, Italy

3. Dipartimento di Scienze Biomediche e Biotecnologie, Università di Cagliari, 09121 Cagliari, Italy

4. SOD Diagnostica, AOU Careggi, 50134 Firenze, Italy

5. Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, 20133 Milan, Italy

6. Department of Reproduction and Growth, Operative Unit of Medical Genetics, University Hospital S. Anna, Ferrara, Italy

7. Department of Public Health, Clinical and Molecular Medicine, University of Cagliari, 09121 Cagliari, Italy

8. Dipartimento di Scienze Biomediche ed Oncologia Umana, University of Bari, 70124 Bari, Italy

9. Laboratory of Molecular Genetics, Istituto Auxologico Italiano, Cusano Milanino, 20135 Milano, Italy

10. Laboratorio di Genetica Medica, Fondazione IRCCS Policlinico Ca' Granda Ospedale, Milano, Italy

11. Unit of Hereditary Cancer, Department of Epidemiology, Prevention and Special Functions, Istituto Nazionale per la Ricerca sul Cancro (IST), Genova, Italy

Abstract

Since 2001 the Istituto Superiore di Sanità established a quality assurance programme for molecular genetic testing that covers four pathologies: Cystic Fibrosis (CF), Beta Thalassemia (BT), Fragile X Syndrome (FX), and Familial Adenomatous Polyposis Coli (APC). Since 2009 this activity is an institutional activity and participation is open to both public and private laboratories. Seven rounds have been performed until now and the eighth is in progress. Laboratories receive 4 DNA samples with mock clinical indications. They analyze the samples using their routine procedures. A panel of assessors review the raw data and the reports; all data are managed through a web utility. In 2010 the number of participants was 43, 17, 15, 5 for CF, BT, FX, APC schemes respectively. Genotyping results were correct in 96%, 98.5%, 100%, and 100% of CF, BT, FX, and APC samples, respectively. Interpretation was correct in 74%, 91%, 88%, and 60% of CF, BT, FX, and APC reports, respectively; however in most of them it was not complete but a referral to genetic counseling was given. Reports were satisfactory in more than 60% of samples in all schemes. This work presents the 2010 results in detail comparing our data with those from other European schemes.

Publisher

Hindawi Limited

Subject

General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Medicine

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3